GE readies new Logiq alpha line
GE Medical Systems of Milwaukee is preparing for the commercialintroduction of two new ultrasound scanners, the first membersof a new Logiq alpha family of analog black-and-white systemsfor the entry-level and mid-range segments.Designed and produced by
GE Medical Systems of Milwaukee is preparing for the commercialintroduction of two new ultrasound scanners, the first membersof a new Logiq alpha family of analog black-and-white systemsfor the entry-level and mid-range segments.
Designed and produced by GEMS India, Logiq alpha 100 is a small,portable scanner that features a software-controlled architecturewith continuously adjusted dynamic focus for echo-sensitive, 256-shadegray-scale images, according to the company. GE included informationabout the scanner in its press kit at this month's European Congressof Radiology meeting in Vienna.
Logiq alpha 100 weighs 9.8 kg and is compatible with advancedconvex and microconvex probes. The system is suitable for a widerange of studies, including ob/gyn, gastroenterology, and urology,according to GE.
GE's Japanese subsidiary, YMS, has started sales of both Logiqalpha 100 and another new member of the Logiq alpha series, Logiqalpha 200, according to Comline News Service. Logiq alpha 200features an aperture area for wave emission and reception 1.7times as wide as conventional systems. Logic alpha 200 receivedFood and Drug Administration clearance in August 1996.
As of press time, GE ultrasound executives could not be reachedfor comment on whether the Logiq alpha line will be sold in theU.S.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
